Clear All
11398 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
57894-0080-90 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
00069-1198-30 00069-1198 dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
60687-0882-21 60687-0882 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 19, 2025 In Use
00069-0197-30 00069-0197 dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
81927-0201-01 81927-0201 Imatinib oral IMKELDI 80.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 19, 2024 In Use
64842-0120-05 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb 3, 2023 In Use
00469-1425-21 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 30, 2022 In Use
00597-0145-60 00597-0145 Nintedanib Ofev 150.0 mg/1, 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Oral Oct 17, 2014 In Use
42291-0939-12 42291-0939 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Apr 23, 2024 In Use
00069-0227-01 00069-0227 Lorlatinib Lorbrena 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Oral Nov 19, 2018 In Use
62856-0724-05 62856-0724 Lenvatinib Lenvima Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb 13, 2015 In Use
73207-0303-41 73207-0303 Vimseltinib ROMVIMZA 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R Oral Feb 14, 2025 In Use
73207-0302-40 73207-0302 Vimseltinib ROMVIMZA 14.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R Oral Feb 14, 2025 In Use
59651-0466-29 59651-0466 SUNITINIB MALATE SUNITINIB MALATE 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Mar 14, 2024 In Use
65597-0407-20 65597-0407 Pexidartinib hydrochloride Turalio 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Feb 1, 2023 In Use
73207-0304-40 73207-0304 Vimseltinib ROMVIMZA 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R Oral Feb 14, 2025 In Use
62856-0704-30 62856-0704 Lenvatinib Lenvima 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Aug 15, 2018 In Use
00069-0504-30 00069-0504 Bosutinib BOSULIF 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 2, 2024 In Use
54868-5289-02 54868-5289 Imatinib Mesylate Gleevec Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct 7, 2005 Jun 30, 2013 No Longer Used
73207-0303-40 73207-0303 Vimseltinib ROMVIMZA 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R Oral Feb 14, 2025 In Use
00003-0527-11 00003-0527 Dasatinib Sprycel 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 27, 2006 In Use
73207-0304-41 73207-0304 Vimseltinib ROMVIMZA 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R Oral Feb 14, 2025 In Use
68001-0622-05 68001-0622 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 6, 2024 In Use

Found 11398 results — Export these results